Novo Nordisk’s quarterly beat and guidance increase did little to resolve Wall Street’s biggest concern: whether the Ozempic maker has a convincing path back to sustainable growth as competition from Eli Lilly intensifies. Analysts said the better-than-expected quarter benefited from rebate adjustments and other temporary factors, obesity drug sales were broadly in line with expectations,…
Pfizer Inc. signage on the floor of the New York Stock Exchange (NYSE) in New York, US, on Wednesday, March 4, 2026. Michael Nagle | Bloomberg | Getty Images Pfizer on Tuesday reported second-quarter results that topped estimates and hiked the low end of its revenue outlook, citing an added $1.5 billion in sales from…
The exterior view of the entrance to Merck headquarters in Rahway, New Jersey, on Feb. 5, 2024. Spencer Platt | Getty Images Merck on Tuesday beat second-quarter estimates and hiked its revenue outlook, as a slate of new products showed strong growth. But the pharmaceutical giant cut its profit guidance due to a charge tied…
AstraZeneca shares dropped as much as 7% after a report that the U.K.’s largest drugmaker was in talks with U.S. peer Bristol Myers Squibb over a megadeal that, if completed, could value the companies at roughly $400 billion. AstraZeneca declined to comment. Bristol Myers Squibb didn’t immediately respond to a request to comment outside of…
A smart acquisition strategy has made Bristol-Meyers, which has bought seven companies since October 2007, a big player in the cancer-treatment industry. Its purchase of Medarex in July added a key drug for metastic melanoma that’s in Phase III trials. The drug has possible multiple indications – industry jargon for its ability to treat more…
A pharmacy at a Costco store in Teterboro, New Jersey, US, on Wednesday, Feb. 28, 2024. Bloomberg | Bloomberg | Getty Images As more Americans use GLP-1 weight-loss drugs to shrink their waistlines, retail giants are betting on a bottom-line bump tied to a shift in the way the drugs are priced and purchased. Employers…
Novo Nordisk shareholders are suing the drugmaker over its experimental obesity treatment CagriSema, alleging the company misled investors about a key clinical trial before releasing disappointing results that wiped billions of dollars off its market value. A federal judge on Tuesday allowed parts of that lawsuit to move forward, finding that investors had plausibly alleged…
The boom in GLP-1 weight-loss drugs and other specialized medicines has created lucrative logistics opportunities in an industry that pays a premium for reliability, visibility, and regulatory know-how. The expertise needed to properly transport these temperature-sensitive therapies is just part of the reason why FedEx created a dedicated unit to handle what has become a…
A customer shops for cilantro at a Walmart Supercenter on July 23, 2026, in Austin, Texas. Brandon Bell | Getty Images The nation’s largest multistate outbreak of cyclosporiasis linked to shredded iceberg lettuce has expanded to nine states, the Centers for Disease Control and Prevention said Friday. The four newly linked states — Illinois, Kansas,…
A visitor walks next to the logo of the Indian multinational pharmaceutical company Dr. Reddy’s Laboratories during the Bio Asia 2026 summit in Hyderabad, Telangana, India, on February 18, 2026. (Photo by Jwala Kotesh/NurPhoto via Getty Images) Nurphoto | Nurphoto | Getty Images U.S. President Donald Trump’s proposed tariffs on generic drugs will increase the…
